So last week, the left lost its mind because the price of Epipens skyrocketed. Epipens are these things that you use if you have a bee sting and you go into anaphylactic shock. Hillary Clinton quickly jumped on this story. She characterized it as a failure of capitalism. She said, quote, millions of Americans with severe reactions rely on their epipens. Over the last several years years, Milan Pharmaceuticals has increased the price of

EpiPens by more than 400%. That's outrageous, and it's just the latest troubling example of a company

taking advantage of its consumers. Naturally, as always, Hillary called for more regulation,

but there's a reason EpiPens have skyrocketed in price, and it's not because the company is super-duper

mean to little kids who suffer

from bee stings. Here are the two real reasons why EpiPen's got so expensive, so fast. First,

insurance coverage masks the increase. So insurers and employers typically negotiate with

myelin pharmaceuticals over EpiPen prices. That means end users didn't have any clue about the

price increases until they lost their insurance or until their deductibles jumped.

So thanks Obamacare for forcing parents into position where they had to pay cash for the EpiPens or pay more for their insurance coverage.

Mylan has actually been giving coupons to consumers, to consumers for co-payments on commercial insurance.

They've handed out 700,000 EpiPens to public schools for free, but Obamacare has made people feel the pain via their insurance companies, because now they have to buy the insurance or they have to pay a fine. Mylan CEO, Heather Bresh, who by the way is the daughter of a Democratic senator, says, quote, we recognize the significant burden on patients from continued rising insurance premiums and being forced to pay

the full list price for medicines at the pharmacy council. So thanks, Obama. Second reason. The federal

government prevents competition. So EpiPen could only jack up prices because they have no competition

in the marketplace. EpiPen doesn't cost 600 bucks in Europe. That's weird that they were able to

escape competition, given that epinephrine, which is the key component in the epipens, isn't patented. It's been synthesized for well over a century. In Europe, there are lots of competitors to the EpiPen, but in the United States, the FDA has actually prevented competitors from entering the market. The biggest competitor to EpiPen, which is called Adrenoclic, is barred from

substitution for EpiPen and prescriptions. So what that means is that if your doctor writes down

EpiPen, normally your pharmacist can give you the generic version, they can't under law. Obviously,

EpiPen lobbies to prevent competition. So far, they've succeeded. The solution here isn't to

remove the government regulation, isn't to

create more government regulations that would ensure more competition in the insurance and medical

device marketplace. The solution is price controls according to the left, right? That would make

...